An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)

Part of paid clinical trials in Salem, Oregon.

Sponsor
CytoDyn, Inc.
Study ID
NCT07536815
Status
Available

Conditions

  • TNBC
  • TNBC - Triple-Negative Breast Cancer
  • TNBC, Triple Negative Breast Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • leronlimab (PRO 140) — DRUG
    Leronlimab is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.

Study Details

This Expanded Access Program provides investigational access to leronlimab (PRO 140) for patients with advanced or metastatic triple-negative breast cancer (TNBC) who lack satisfactory treatment options and are unable to participate in a clinical trial.

Key Dates

Status verified
Mar 2026

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Oregon Oncology SpecialistsSalemOregon97301-

Find similar trials in Salem, OR

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Oregon Oncology Specialists· Salem, OR

Related Studies